IP Library › Granted Patent US 10,106,622
Granted Patent B2
US 10,106,622 · App. 15/501,843 · Granted Oct 23, 2018

Human antibody specific to c-Met and preparation method thereof

Inventors: Jinsang Yoo (Daejeon, KR); Ju Ryoung Nam (Daejeon, KR); Jin San Yoo (Daejeon, KR); Sung-Woo Kim (Daejeon, KR); Weon Sup Lee (Daejeon, KR); Sang Ryeol Shim (Daejeon, KR); Sang Soon Byun (Daejeon, KR); Miju Park (Daejeon, KR); Hyuk Joon Lee (Daejeon, KR); Do Yun Kim (Chungcheongbuk-do, KR); Yeon Ju Kim (Daejeon, KR); Mi Ae Jeon (Daejeon, KR); Jinhee Choi (Daejeon, KR); Youngae Lee (Daejeon, KR); Kyoung Hee Nahm (Daejeon, KR); Boyoung Jeong (Daejeon, KR); Seon Young Lee (Seoul, KR); Jong Geun Jeong (Daejeon, KR); Jae Bong Yoon (Daejeon, KR); Nam Ye Kim (Daejeon, KR); Seon Hwan Oh (Daejeon, KR); Eun Hee Lee (Daejeon, KR); Ji Hye Jeong (Daejeon, KR)
Assignee: PHARMABCINE INC.
C07K16/32A61K2039/505C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,622
App. No.
15/501,843
Granted
Oct 23, 2018
Kind
B2
Abstract

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Claims (10)

1. A c-Met-specific antibody or an antigen binding fragment thereof comprising:

a heavy chain variable region CDR1 having the amino acid sequence of SEQ ID NO: 1; a heavy chain variable region CDR2 having the amino acid sequence of SEQ ID NO: 2; and a heavy chain variable region CDR3 having the amino acid sequence SEQ ID NO: 3; and

a light chain variable region CDR1 having the amino acid sequence of SEQ ID NO: 4; a light chain variable region CDR2 having the amino acid sequence of SEQ. ID NO: 5; and a light chain variable region CDR3 having the amino acid sequence of SEQ ID NO: 6.

2. The c-Met-specific antibody or the antigen binding fragment thereof according to claim 1 , wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO:7.

3. The c-Met-specific antibody or the antigen binding fragment thereof according to claim 1 , wherein the light chain variable region has the amino acid sequence of SEQ ID NO:8.

4. A polynucleotide encoding the c-Met-specific antibody or the antigen binding fragment thereof according to any one of claims 1 to 3 .

5. The polynucleotide according to claim 4 , comprising the nucleotide sequence of SEQ ID NO: 11 or SEQ ID NO: 12.

6. A recombinant expression vector comprising the polynucleotide encoding the c-Met-specific antibody or the antigen binding fragment thereof according to claim 4 .

7. A host cell transformed with the recombinant expression vector according to claim 6 .

8. A method of producing a c-Met-specific antibody or an antigen binding fragment thereof according to claim 1 comprising: culturing the host cell according to claim 7 , and recovering the c-Met-specific antibody or the antigen binding fragment thereof from the culture.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2017
From: YOO, JINSANG; NAM, JU RYOUNG; YOO, JIN SAN; KIM, SUNG-WOO; LEE, WEON SUP; SHIM, SANG RYEOL; BYUN, SANG SOON; PARK, MIJU; LEE, HYUK JOON; KIM, DO YUN; KIM, YEON JU; JEON, MI AE; CHOI, JINHEE; LEE, YOUNGAE; NAHM, KYOUNG HEE; JEONG, BOYOUNG; LEE, SEON YOUNG; JEONG, JONG GEUN; YOON, JAE BONG; KIM, NAM YE; OH, SEON HWAN; LEE, EUN HEE; JEONG, JI HYE
To: PHARMABCINE INC.
Reel/Frame 041264/0452 →
Priority Claims (1)
KR 10-2014-010557 · Aug 7, 2014 · national
Continuity (1)
Related Publication 20170233492A1 · Aug 17, 2017
Cited By (3)
US 12,545,735 US 12,570,719 US 12,605,473